Form 4: ANI Pharma Exec's Tax-Related Stock Sale

Krista Davis, SVP, Chief HR Officer of ANI Pharmaceuticals, disposed of 1,710 shares of common stock for tax purposes related to restricted stock vesting.

Summary

• Krista Davis, SVP, Chief HR Officer of ANI Pharmaceuticals, reported a transaction involving the company's common stock.
• The transaction occurred on September 12, 2025, and involved the disposition of 1,710 shares.
• These shares were withheld for tax purposes, exempt under Rule 16(b)-3, in connection with the vesting of 4,108 shares of previously granted restricted stock.
• The shares were disposed of at a price of $97.71 per share.
• Following this transaction, Krista Davis beneficially owns 61,186 shares of ANI Pharmaceuticals common stock directly.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary event related to tax withholding upon restricted stock vesting, which is neutral in terms of market sentiment.

Future Outlook

This filing does not contain any forward-looking statements or guidance.

Industry Context

This is a routine insider transaction related to executive compensation and tax obligations, which is common across all industries for publicly traded companies.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine, non-discretionary transaction for tax purposes, not indicative of a change in insider sentiment or company fundamentals.

Key Dates

Recommendation

The filing reports a routine, non-discretionary transaction where shares were withheld for tax purposes upon the vesting of restricted stock. This type of insider transaction does not reflect a change in management's outlook or a discretionary sale, and therefore, does not warrant a change in investment recommendation based solely on this filing.

Keywords

ANI Pharmaceuticals, ANIP, Krista Davis, Form 4, Insider Transaction, Restricted Stock, Tax Withholding, Beneficial Ownership